SYNBIOTIC SE
ISIN: DE000A3E5A59
WKN: A3E5A5
25 November 2024 11:39AM

EQS-News: SYNBIOTIC integrates greensby: Universal platform for the entire hemp and cannabis industry

SYNBIOTIC SE · ISIN: DE000A3E5A59 · EQS - Company News
Land: Deutschland · Primärmarkt: Deutschland · EQS News ID: 2037659

EQS-News: SYNBIOTIC SE / Key word(s): Mergers & Acquisitions
SYNBIOTIC integrates greensby: Universal platform for the entire hemp and cannabis industry

25.11.2024 / 11:39 CET/CEST
The issuer is solely responsible for the content of this announcement.


The European hemp and cannabis group SYNBIOTIC SE (ISIN DE000A3E5A59 | WKN A3E5A5) announces the integration of greensby with the acquisition of 50.2 % of the shares. This strategic move creates a unique platform that bundles all of the Group's products and services and comprehensively covers the entire hemp and cannabis market.

greensby is a central platform that connects patients, pharmacies, telemedicine providers and consumers and enables the comparison of cannabis products. Following its integration into SYNBIOTIC, greensby is now expanding its range to include hemp products and cultivation accessories for recreational cannabis, offering up to 4,000 products. This makes greensby a comprehensive point of contact for all hemp and cannabis-related needs.

Only greensby compares in this way

greensby is one of the largest comparison portals for medicinal cannabis in Europe. Here, users can find information on all the prices of the most popular pharmacies and also find separate subpages for each strain with useful information, batch-dependent cannabinoid and terpene profiles. The sophisticated rating system also allows users to find a strain that has already helped other people with similar symptoms. The aim is to make greensby the most visited portal in the cannabis industry.

"A question that has been driving me for some time: What if a single platform could unite all the needs of the hemp and cannabis industry? With greensby, we're making that possible," explains Emilio Ropero, CCO SYNBIOTIC. "From cannabis patients to consumers - we are creating an interface to optimally cover the needs of all market participants.

The greensby platform is user-friendly, customer-orientated and indexes the entire market. This makes it an absolute added value in terms of marketing for everyone involved - from consumers to our partners and investors."

Everything under one roof

For pharmacies, greensby offers a comprehensive solution that significantly simplifies entry into the medical cannabis market. In addition to a comprehensive database with information on products, terpene profiles and batches, user-friendly software with integrated inventory, payment options and interfaces to wholesalers is available. All processes, from ordering to delivery, are efficiently organised also thanks to the logistical connection to partners such as DHL and GO. In addition, training is offered for pharmacy staff to ensure that they are always up to date.

Prescribers of cannabis medicines, including telemedicine practitioners, benefit from trustworthy information on medicinal cannabis and a daily updated inventory overview of pharmacies. This enables better care for patients and significantly reduces waiting times for required medication.

Patients are at the centre of greensby. The platform simplifies the entire process, from the consultation with the doctor to the delivery of medication. Patients can compare and evaluate strains and view their availability in pharmacies. A specially developed digital assistant supports the selection of strains and, if desired, refers patients directly to prescribers of cannabis medicines.

Daniel Kruse, Managing Director of SYNBIOTIC, emphasises: "Our absolutely unique selling point is that our buy-and-build strategy unites the entire industry on one platform - and we are now also presenting this in digitalised form on greensby.de. There is nothing like this on the market yet. We are creating a transparent, optimised and accessible solution for everyone involved."

Adam Szajcz, CEO of greensby, adds: "With greensby, we are facilitating communication and interaction across the entire industry. Among other things, we are connecting hundreds of pharmacies and creating Germany's largest community for cannabis patients. We will be releasing a new version of our platform in December, on which we will also integrate the other business areas of the SYNBIOTIC Group."

Shaping the future together

With the integration of greensby, SYNBIOTIC is taking a decisive step towards digitalisation and increased efficiency. The platform invites the community, partners and investors to play an active role in shaping the future of the industry. It is more than just a project - greensby is part of the future of the hemp and cannabis industry.

Publisher
SYNBIOTIC SE
Daniel Kruse
Managing Director
Münsterstrasse 336
40470 Düsseldorf
Germany

Media contact
Rüdiger Tillmann
SYNBIOTIC
Public Relations Manager
E-mail ruediger.tillmann@synbiotic.com
Mobile +49 170 9651451
c/o JOLE.group

About SYNBIOTIC
SYNBIOTIC is a publicly listed group of companies in the hemp and cannabis sector with a buy-and-build investment strategy focussed on the EU.
The Group covers the entire value chain from cultivation to production and retail - from the field to the shelf. The subsidiaries' core businesses are research and development, production and the commercialisation of hemp, CBD and cannabis products.
SYNBIOTIC is pursuing a clear pan-European strategy to further expand along the value chains of its business areas - hemp and CBD, medical cannabis and consumer cannabis - and thus cover the relevant growth markets while increasing opportunities for investors through diversification.


25.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SYNBIOTIC SE
Münsterstr. 336
40470 Dusseldorf
Germany
E-mail: office@synbiotic.com
Internet: https://www.synbiotic.com/
ISIN: DE000A3E5A59
WKN: A3E5A5
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Tradegate Exchange
EQS News ID: 2037659

 
End of News EQS News Service

2037659  25.11.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2037659&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Zur besseren Einschätzung der fundamentalen Entwicklung der jeweiligen Unternehmen bietet boersengefluester.de (BGFL) eine Übersicht mit den wesentlichen Kennzahlen zu Umsatz, Ergebnis, Cashflow und Dividende. Sämtliche Angaben werden manuell in unserer Datenbank erfasst – Quelle sind die jeweiligen Geschäftsberichte. Sofern es sich um Schätzungen für künftige Zahlen handelt, stammen sie durchweg von BGFL. 

Die wichtigsten Finanzdaten auf einen Blick
  2018 2019 2020 2021 2022 2023 2024e
Umsatzerlöse1 0,00 0,00 5,45 8,65 8,17 3,86 16,30
EBITDA1,2 0,00 -0,01 -0,71 -4,83 -7,41 -7,19 2,00
EBITDA-Marge3 0,00 0,00 -13,03 -55,84 -90,70 -186,27 12,27
EBIT1,4 0,00 -0,01 -0,83 -11,49 -25,92 -11,75 -1,90
EBIT-Marge5 0,00 0,00 -15,23 -132,83 -317,26 -304,40 -11,66
Jahresüberschuss1 0,00 -0,01 -0,88 -13,07 -26,00 -11,74 -2,55
Netto-Marge6 0,00 0,00 -16,15 -151,10 -318,24 -304,15 -15,64
Cashflow1,7 0,00 -0,01 -1,26 -5,14 -6,99 -2,92 0,00
Ergebnis je Aktie8 0,00 0,00 -0,56 -4,15 -5,97 -2,25 -0,43
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben
Legende

1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Forvis Mazars

Alle relevanten Bewertungskennzahlen, Termine und sonstige Investor-Informationen zu Ihrer Aktie kompakt zusammengefasst. Gut zu wissen: Sämtliche Daten stammen von boersengefluester.de werden täglich aktualisiert. Damit sind Sie immer auf dem neuen Stand. Kurze Erkärungen zu den Kennzahlen bekommen Sie, wenn Sie mit dem Cursor bzw. der Maus auf das jeweilige Feld gehen.

INVESTOR-INFORMATIONEN
©boersengefluester.de
SynBiotic
WKN ISIN Rechtsform Börsenwert IPO Einschätzung Plus Code
A3E5A5 DE000A3E5A59 SE 27,98 Mio € 11.11.2019 Halten 9F387R32+8V
* * *
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV KBV KCV KUV
37,27 0,00 0,00 -1,53 1,83 -9,57 7,25
Dividenden
Dividende '2022
in €
Dividende '2023
in €
Dividende '2024e
in €
Div.-Rendite '2024e
in %
0,00 0,00 0,00 0,00%
Finanztermine
Hauptversammlung Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
20.09.2024 30.09.2024 14.08.2024
Performance-Angaben
Abstand 60-Tage-Linie Abstand 200-Tage-Linie Performance YtD Kursveränderung 52 Wochen IPO
Akt. Kurs (EoD)
-2,15%
4,10 €
ATH 41,80 €
-28,93% -44,78% +38,98% +36,67% +318,71%

Werbung ist für uns ein wichtiger Einnahmekanal. Aber wir verstehen, dass sie manchmal lästig wird. Wenn Sie die Anzahl der angezeigten Werbung reduzieren möchten, loggen Sie sich einfach in Ihr Benutzerkonto ein und verwalten Sie die Einstellungen von dort aus. Als registrierter Benutzer erhalten Sie viele Vorteile.
          Qualitätsjournalismus · 2013-2024 · Made in Germany          
Die Nachrichtenmanufaktur

Informierte Anleger treffen bessere Entscheidungen

Auf dem 2013 von Gereon Kruse gegründeten Finanzportal boersengefluester.de dreht sich alles um deutsche Aktien – mit klarem Schwerpunkt auf Nebenwerte. Neben klassischen redaktionellen Beiträgen sticht die Seite insbesondere durch eine Vielzahl an selbst entwickelten Analysetools hervor. Basis sämtlicher Tools ist eine komplett selbst gepflegte Datenbank für mehr als 650 Aktien. Damit erstellt boersengefluester.de Deutschlands größte Gewinn- und Dividendenprognose.

Kontakt

Idee & Konzept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 von Gereon Kruse #BGFL